Skip to main content
SpringerLink
Log in

Adverse Effects Encountered During IGF-I Treatment of Patients with Laron Syndrome

  • Chapter
  • First Online:
Laron Syndrome - From Man to Mouse

Core Message

Following IGF-I administration the following adverse effects have been observed in our cohort: hypoglycemia, headaches, hyperandrogenism, obesity, snoring and sleep apnea. These and further adverse effects have been reported by the investigators using two IGF-I injections a day. Most are probably linked to IGF-I over dosage.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Azcona C, Preece MA, Rose SJ, Fraser N, Rappaport R, Ranke MB, Savage MO (1999) Growth response to rhIGF-I 80 µg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype. Clin Endocrinol (Oxf) 51:787–792

    Article  CAS  Google Scholar 

  • Backeljauw PF, Underwood LE (1996) Prolonged treatment with recombinant insulin-like growth factor-1 in children with growth hormone insensitivity syndrome – a clinical research center study. J Clin Endocrinol Metab 81:3312–3317

    Article  PubMed  CAS  Google Scholar 

  • Backeljauw PF, Underwood LE, The GHIS Collaborative Group (2001) Therapy for 6.5–7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metabol 86:1504–1510

    Article  CAS  Google Scholar 

  • Ben-Amitai D, Laron Z (2009) Insulin-like growth factor-1 (IGF-1) deficiency prevents the appearance of pre-acne and acne (Abstract PO2-186) 8th Joint Meeting of the LWPES/ESPE, New York, 9–12 Sep 2009. Horm Res 73(suppl 3):265–266. Full paper in J Eur Acad Dermatol Venerol 2010 (in press)

    Google Scholar 

  • Besson A, Salemi S, Eble A, Joncourt F, Gallati S, Jorge AA, Mullis PE (2004) Primary GH insensitivity (Laron syndrome) caused by a novel 4 kb deletion encompassing exon 5 of the GH receptor gene: effect of intermittent long-term treatment with recombinant human IGF-I. Eur J Endocrinol 150:635–642

    Article  PubMed  CAS  Google Scholar 

  • Camacho-Hubner C, Underwood LE, Yordam N, Yuksel B, Smith AV, Attie KM, Savage MO; The GHIS Multicenter Study Group (2006) Once daily rhIGF-I/rhIGFBP-3 treatment improves growth in children with severe primary IGF-I deficiency: results of a multicenter clinical trial. (Abstract OR40-1) 88th Annual Meeting of the Endocrine Society. Boston, p 132

    Google Scholar 

  • Chernausek SD, Underwood L, Kuntze J, Frane J, Bright GM (2004) Safety of recombinant insulin-like growth factor-1 (rhIGF-I) in the treatment of children with IGF deficiency (IGFD) due to GH insensitivity: 231 treatment-years of experience. (Abstract P3-450) 86th Annual Meeting of the Endocrine Society. New Orleans, p 575

    Google Scholar 

  • Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE; GH Insensitivity Syndrome Collaborative Group (2007) Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 92:902–910

    Google Scholar 

  • Dagan Y, Abadi J, Lifschitz A, Laron Z (2001) Severe obstructive sleep apnoea syndrome in an adult patient with Laron syndrome. Growth Horm IGF Res 11:247–249

    Article  PubMed  CAS  Google Scholar 

  • Frane J, Bailly J, Chernausek SD, Kuntze J (2006) Growth responses to higher dose recombinant human IGF-I (rhIGF-I) in children with severe primary IGF-I deficiency (IGFD) due to growth hormone insensitivity (GHIS) (abstract P03-619). Horm Res 65(suppl 4):180

    Google Scholar 

  • Guevara-Aguirre J, Vasconez O, Martinez V, Martinez AL, Rosenbloom AL, Diamond FB Jr, Gargosky SE, Nonoshita L, Rosenfeld RG (1995) A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab 80:1393–1398

    Article  PubMed  CAS  Google Scholar 

  • Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Allen L, Rosenfeld RG (1997) Two year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab 82:629–633

    Article  PubMed  CAS  Google Scholar 

  • Klinger B, Anin S, Silbergeld A, Eshet R, Laron Z (1998) Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome. Clin Endocrinol 48:81–87

    Article  CAS  Google Scholar 

  • Krzisnik C, Battelino T (1997) Five year treatment with IGF-I of a patient with Laron syndrome in Slovenia (a follow-up report). J Pediatr Endocrinol Metab 10:443–447

    Article  PubMed  CAS  Google Scholar 

  • Laron Z (2008) Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity). Pediatr Endocrinol Rev 5:766–771

    PubMed  Google Scholar 

  • Laron Z, Silbergeld A, Klinger B (1998) Hyperandrogenism induced by insulin-like growth factor-I (IGF-I) treatment of two girls with Laron Syndrome. Child Hosp Quart 10:75–79

    Google Scholar 

  • Laron Z, Klinger B, Silbergeld A (1999) Serum insulin like growth factor I (IGF-I) levels during long term IGF-I treatment in children and adults with primary GH resistance (Laron syndrome). J Pediat Endocrinol Metab 12:145–152

    CAS  Google Scholar 

  • Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N (2006) Long-term IGF-I treatment of children with Laron syndrome increases adiposity. Growth Horm IGF Res 16:61–64

    Article  PubMed  CAS  Google Scholar 

  • Laron Z, Ginsberg S, Webb M (2008) Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion – preliminary report. Growth Horm IGF Res 18:434–438

    Article  PubMed  CAS  Google Scholar 

  • Lordereau-Richard I, Roger M, Chaussain JL (1994) Transient bilateral papilloedema in a 10-year-old boy treated with recombinant insulin-like growth factor I for growth hormone receptor deficiency. Acta Paediatr Suppl 399:152

    Article  PubMed  CAS  Google Scholar 

  • Metz KA, Assa’ad A, Lierl MB. Backeljauw P (2009) Allergic reaction to mecasermin. Ann Allergy, Asthma, Immunol 103:82–83

    Article  Google Scholar 

  • Ranke MB, Wilton P (1994) Adverse events during treatment with recombinant insulin-like growth factor I in patients with growth hormone insensitivity. Acta Paediatr Suppl 399:143–145

    Article  PubMed  CAS  Google Scholar 

  • Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Blum WF, Wilton P (1995) Insulin-like growth factor I improves height in growth hormone insensitivity: two years’ results. Horm Res 44:253–264

    Article  PubMed  CAS  Google Scholar 

  • Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P; The Working Group on Growth Hormone Insensitivity Syndromes (1999) Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res 51:128–134

    Article  Google Scholar 

  • Savage MO, Attie KM, David A, Metherell LA, Clark AJ, Camacho-Hubner C (2006a) Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders. Nat Clin Pract Endocrinol Metab 2:395–407

    Article  PubMed  CAS  Google Scholar 

  • Savage MO, Underwood L, Yordam N, Yuksel B, Smith A, Attie K, Camacho Hubner C (2006b) Treatment of short stature in children with severe primary IGF-I deficiency with once daily rhIGF-I/rhIGFBP-3 administration [abstract CF1-100]. Horm Res 65(suppl 4):30

    Google Scholar 

  • Vasconez O, Martinez V, Martinez AL, Hidalgo F, Diamond FB, Rosenbloom AL, Rosenfeld RG, Guevara-Aguirre J (1994) Heart rate increases in patients with growth hormone receptor deficiency treated with insulin-like growth factor I. Acta Paediatr Suppl 399:137–139

    Article  PubMed  CAS  Google Scholar 

  • Walker JL, Van Wyk JJ, Underwood LE (1992) Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type). J Pediatr 121:641–646

    Article  PubMed  CAS  Google Scholar 

  • Walker JL, Crock PA, Behncken SN, Rowlinson SW, Nicholson LM, Boulton TJC, Waters MJ (1998) A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-1 and luteinizing hormone-releasing hormone analogue. J Clin Endocrinol Metab 83:2554–2561

    Article  PubMed  CAS  Google Scholar 

  • Wollman HA, Ranke MB (1994) Bell’s palsy after onset of insulin-like growth factor I therapy in a patient with growth hormone receptor deficiency. Acta Paediatr Suppl 399:148–149

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Unit, Schneider Children’s Medical Center of Israel, Kaplan Street 14, 49202, Petah Tikva, Israel

    Zvi Laron

Authors
  1. Zvi Laron
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zvi Laron .

Editor information

Editors and Affiliations

  1. Endocrinology & Diabetes Research Unit, Schneider Children's Hospital, Kaplan Street 14, Petah Tikva, 49 202, Israel

    Zvi Laron

  2. Edison Biotechnology Institute, Ohio University, Athens, 45701, Ohio, USA

    J. Kopchick

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Laron, Z. (2011). Adverse Effects Encountered During IGF-I Treatment of Patients with Laron Syndrome. In: Laron, Z., Kopchick, J. (eds) Laron Syndrome - From Man to Mouse. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-11183-9_47

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-11183-9_47

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-11182-2

  • Online ISBN: 978-3-642-11183-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation